Relationship between gut microbiota and vascular calcification in hemodialysis patients

References

• Yin L, Li X, Ghosh S, et al. Role of gut microbiota-derived metabolites on vascular calcification in CKD. J Cell Mol Med. 2021;25(3):1332–1341.
   PubMed Web of Science ®Google Scholar
• Liu ZH, Li G, Zhang L, et al. Executive summary: clinical practice guideline of chronic kidney Disease - Mineral and bone disorder (CKD-MBD) in China. Kidney Dis. 2019;5(4):197–203.
   Google Scholar
• Hsu BG, Tsai JP. Vascular calcification of chronic kidney disease: a brief review. Tzu Chi Med J. 2021;33(1):34–41.
   PubMed Web of Science ®Google Scholar
• Disthabanchong S. Vascular calcification in chronic kidney disease: pathogenesis and clinical implication. World J Nephrol. 2012;1(2):43–53.
   PubMedGoogle Scholar
• He L, He WY, La-Ta TA, et al. Lower serum Irisin levels are associated with increased vascular calcification in hemodialysis patients. Kidney Blood Press Res. 2018;43(1):287–295.
   PubMed Web of Science ®Google Scholar
• Bao WH, Wang Y. Alterations and influences of gut microbiota in chronic kidney disease. Chin Gen Pract. 2018;21(24):2927–2931.
   Google Scholar
• Opdebeeck B, Maudsley S, Azmi A, et al. Indoxyl sulfate and p-Cresyl sulfate promote vascular calcification and associate with glucose intolerance. J Am Soc Nephrol. 2019;30(5):751–766.
   PubMed Web of Science ®Google Scholar
• Guasti L, Galliazzo S, Molaro M, et al. TMAO as a biomarker of cardiovascular events: a systematic review and meta-analysis. Intern Emerg Med. 2021;16(1):201–207.
   PubMed Web of Science ®Google Scholar
• Shafi T, Powe NR, Meyer TW, et al. Trimethylamine N-Oxide and cardiovascular events in hemodialysis patients. J Am Soc Nephrol. 2017;28(1):321–331.
   PubMed Web of Science ®Google Scholar
• Luo D, Zhao W, Lin Z, et al. The effects of hemodialysis and peritoneal dialysis on the gut microbiota of End-Stage renal disease patients, and the relationship between gut microbiota and patient prognoses. Front Cell Infect Microbiol. 2021;11:579386.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhao Y. Gut microbiota derived metabolites in cardiovascular health and disease. Protein Cell. 2018;9(5):416–431.
   PubMed Web of Science ®Google Scholar
• Stadlbauer V, Horvath A, Ribitsch W, et al. Structural and functional differences in gut microbiome composition in patients undergoing haemodialysis or peritoneal dialysis. Sci Rep. 2017;7(1):15601.
   PubMedGoogle Scholar
• Hu J, Zhong X, Yan J, et al. High-throughput sequencing analysis of intestinal flora changes in ESRD and CKD patients. BMC Nephrol. 2020;21(1):12.
   PubMed Web of Science ®Google Scholar
• Liu ZH, Yu XQ, Yang JW, et al. Prevalence and risk factors for vascular calcification in chinese patients receiving dialysis: baseline results from a prospective cohort study. Curr Med Res Opin. 2018;34(8):1491–1500.
   PubMed Web of Science ®Google Scholar
• Kauppila LI, Polak JF, Cupples LA, et al. New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis. 1997;132(2):245–250.
   PubMed Web of Science ®Google Scholar
• Peeters MJ, van den Brand JA, van Zuilen AD, et al. Abdominal aortic calcification in patients with CKD. J Nephrol. 2017;30(1):109–118.
   PubMed Web of Science ®Google Scholar
• Merino-Ribas A, Araujo R, Pereira L, et al. Vascular calcification and the gut and blood microbiome in chronic kidney disease patients on peritoneal dialysis: a pilot study. Biomolecules. 2022;12(7):867.
   PubMed Web of Science ®Google Scholar
• Jiang S, Xie S, Lv D, et al. Alteration of the gut microbiota in Chinese population with chronic kidney disease. Sci Rep. 2017;7(1):2870.
   PubMed Web of Science ®Google Scholar
• Toya T, Ozcan I, Corban MT, et al. Compositional change of gut microbiome and osteocalcin expressing endothelial progenitor cells in patients with coronary artery disease. PLOS One. 2021;16(3):e0249187.
   PubMed Web of Science ®Google Scholar
• Litvak Y, Byndloss MX, Tsolis RM, et al. Dysbiotic proteobacteria expansion: a microbial signature of epithelial dysfunction. Curr Opin Microbiol. 2017;39:1–6.
   PubMed Web of Science ®Google Scholar
• Flannigan KL, Taylor MR, Pereira SK, et al. An intact microbiota is required for the gastrointestinal toxicity of the immunosuppressant mycophenolate mofetil. J Heart Lung Transplant. 2018;37(9):1047–1059.
   PubMed Web of Science ®Google Scholar
• Hu J, Zhong X, Liu Y, et al. Correlation between intestinal flora disruption and protein-energy wasting in patients with end-stage renal disease. BMC Nephrol. 2022;23(1):130.
   PubMed Web of Science ®Google Scholar
• Ramezani A, Raj DS. The gut microbiome, kidney disease, and targeted interventions. J Am Soc Nephrol. 2014;25(4):657–670.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Cai Y, Cui LY, et al. Suppression of gut bacterial translocation ameliorates vascular calcification through inhibiting Toll-Like receptor 9-Mediated BMP-2 expression. Oxid Med Cell Longev. 2019;2019:3415682.
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhang X, Liu H, et al. Dietary protein and gut microbiota composition and function. Curr Protein Pept Sci. 2019;20(2):145–154.
   PubMed Web of Science ®Google Scholar
• Barreto FC, Barreto DV, Liabeuf S, et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol. 2009;4(10):1551–1558.
   PubMed Web of Science ®Google Scholar
• Liabeuf S, Barreto DV, Barreto FC, et al. Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant. 2010;25(4):1183–1191.
   PubMed Web of Science ®Google Scholar
• McFarlane C, Krishnasamy R, Stanton T, et al. Diet quality and Protein-Bound uraemic toxins: investigation of novel risk factors and the role of microbiome in chronic kidney disease. J Ren Nutr. 2021;32(5):542–551.
   PubMed Web of Science ®Google Scholar
• Sato N, Kakuta M, Hasegawa T, et al. Metagenomic profiling of gut microbiome in early chronic kidney disease. Nephrol Dial Transplant. 2021;36(9):1675–1684.
   PubMed Web of Science ®Google Scholar
• Rodrigues FG, Ormanji MS, Heilberg IP, et al. Interplay between gut microbiota, bone health and vascular calcification in chronic kidney disease. Eur J Clin Invest. 2021;51(9):e13588.
   PubMed Web of Science ®Google Scholar
• Vinolo MA, Rodrigues HG, Nachbar RT, et al. Regulation of inflammation by short chain fatty acids. Nutrients. 2011;3(10):858–876.
   PubMed Web of Science ®Google Scholar
• Henke MT, Kenny DJ, Cassilly CD, et al. Ruminococcus gnavus, a member of the human gut microbiome associated with Crohn's disease, produces an inflammatory polysaccharide. Proc Natl Acad Sci USA. 2019;116(26):12672–12677.
   PubMed Web of Science ®Google Scholar
• Agharazii M, St-Louis R, Gautier-Bastien A, et al. Inflammatory cytokines and reactive oxygen species as mediators of chronic kidney disease-related vascular calcification. Am J Hypertens. 2015;28(6):746–755.
   PubMed Web of Science ®Google Scholar
• Viaene L, Behets GJ, Heye S, et al. Inflammation and the bone-vascular axis in end-stage renal disease. Osteoporos Int. 2016;27(2):489–497.
   PubMed Web of Science ®Google Scholar
• Fine RL, Mubiru DL, Kriegel MA. Friend or foe? Lactobacillus in the context of autoimmune disease. Adv Immunol. 2020;146:29–56.
   PubMed Web of Science ®Google Scholar
• Yu L, Han X, Cen S, et al. Beneficial effect of GABA-rich fermented milk on insomnia involving regulation of gut microbiota. Microbiol Res. 2020;233:126409.
   PubMed Web of Science ®Google Scholar
• Parker BJ, Wearsch PA, Veloo A, et al. The genus alistipes: gut bacteria with emerging implications to inflammation, cancer, and mental health. Front Immunol. 2020;11:906.
   PubMed Web of Science ®Google Scholar
• Zafar H, Saier MH. Jr. Gut bacteroides species in health and disease. Gut Microbes. 2021;13(1):1–20.
   PubMed Web of Science ®Google Scholar
• Li AL, Ni WW, Zhang QM, et al. Effect of cinnamon essential oil on gut microbiota in the mouse model of dextran sodium sulfate-induced colitis. Microbiol Immunol. 2020;64(1):23–32.
   PubMed Web of Science ®Google Scholar
• Wang Z, Wang J, Hu J, et al. A comparative study of acarbose, vildagliptin and saxagliptin intended for better efficacy and safety on type 2 diabetes mellitus treatment. Life Sci. 2021;274:119069.
   PubMed Web of Science ®Google Scholar
• Shivani S, Kao CY, Chattopadhyay A, et al. Uremic toxin-producing bacteroides species prevail in the gut microbiota of Taiwanese CKD patients: an analysis using the new Taiwan microbiome baseline. Front Cell Infect Microbiol. 2022;12:726256.
   PubMed Web of Science ®Google Scholar